MY171206A - A method of increasing the effect of an activated-potentiated form of an antibody - Google Patents

A method of increasing the effect of an activated-potentiated form of an antibody

Info

Publication number
MY171206A
MY171206A MYPI2013000107A MYPI2013000107A MY171206A MY 171206 A MY171206 A MY 171206A MY PI2013000107 A MYPI2013000107 A MY PI2013000107A MY PI2013000107 A MYPI2013000107 A MY PI2013000107A MY 171206 A MY171206 A MY 171206A
Authority
MY
Malaysia
Prior art keywords
antibody
activated
potentiated form
increasing
effect
Prior art date
Application number
MYPI2013000107A
Inventor
Oleg Lliich Epshtein
Original Assignee
Oleg Lliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oleg Lliich Epshtein filed Critical Oleg Lliich Epshtein
Priority to MYPI2013000107A priority Critical patent/MY171206A/en
Priority claimed from PCT/IB2011/002350 external-priority patent/WO2012007845A2/en
Publication of MY171206A publication Critical patent/MY171206A/en

Links

Abstract

The preset invention provides a method of increasing the effect of an activated-potentiated form of an antibody to an endogenous biological molecule by combining said endogenous biological molecule with an activated-potentiated form of an antibody to endothelial NO-synthase. The present invention also provides a pharmaceutical composition comprising a) an activated- potentiated form of an antibody to an endogenous biological molecule, and b) an activated-potentiated form of an antibody to NO synthase.
MYPI2013000107A 2011-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody MY171206A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MYPI2013000107A MY171206A (en) 2011-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2011/002350 WO2012007845A2 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
MYPI2013000107A MY171206A (en) 2011-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody

Publications (1)

Publication Number Publication Date
MY171206A true MY171206A (en) 2019-10-02

Family

ID=79178335

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2013000107A MY171206A (en) 2011-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody

Country Status (1)

Country Link
MY (1) MY171206A (en)

Similar Documents

Publication Publication Date Title
CY1121862T1 (en) ANTI-PHF-TAU ANTIBODIES AND USES THEREOF
MX356337B (en) Antibodies against human csf-1r and uses thereof.
AU2016204248A1 (en) Boron-Containing Molecules
EP4036240A3 (en) Transduction buffer
MX342034B (en) Monovalent antigen binding proteins.
MX336682B (en) Antibodies against human csf-1r and uses thereof.
WO2014074648A3 (en) Riboregulator compositions and methods of use
WO2013060867A3 (en) Production of heterodimeric proteins
ECSP14013339A (en) COMPOUNDS WITH NEMATICIATED ACTIVITY
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
UA116092C2 (en) Methods and compositions for weed control
LT2013016A (en) A method of increasing the effect of an activated-potentiated form of an antibody
EA201590173A1 (en) IMMUNOCONGUTS CONTAINING ANTIBODIES TO CD22
EA201590887A1 (en) COMPOSITION
EA201391389A1 (en) CRYSTALS OF ANTIBODIES AGAINST SKLEROSTIN AND COMPOSITIONS ON THEIR BASIS
IN2012MU03723A (en)
MX2014002996A (en) Bispecific anti-egfr/anti igf-1r antibodies.
CL2012003491A1 (en) Compound derived from dihydropyrrole substituted; process to prepare these derivatives in stereoselective form.
MX2015011781A (en) Cell culture media and methods of antibody production.
UY33994A (en) ANTIBODY MOLECULE OF DABIGATRAN AND DERIVATIVES AS ANTICOAGULANT ANTIDOTES
EA201490767A1 (en) CLUSTER GENES BIOSYNTHESIS OF GRILLYLIMICINE AND METHYLRISYLIMICITY
EA201491300A1 (en) COMPOSITION FOR BODY APPLICATION WITH IMPROVED STABILITY
WO2014037519A3 (en) Compositions and methods
MX352837B (en) Method for labeling intracellular and extracellular targets of leukocytes.
EA201391643A1 (en) COMPOSITIONS WITH DELAYED PARACETAMOL DELIVERY